{"id":"W4388084017","doi":"10.1016/j.jtho.2023.09.057","title":"OA09.04 ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"National Defence Medical Centre","funders":"","keywords":"Durvalumab; Medicine; Pemetrexed; Tremelimumab; Lung cancer; Epidermal growth factor receptor; Chemotherapy; Oncology; Tolerability; Internal medicine; Cisplatin; Pembrolizumab; Cancer; Immunotherapy; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009588717,0.0002007403,0.0006764077,0.000200569,0.0001401754,0.0006304829,0.0002967457,0.0003206827,0.003635712],"category_scores_gemma":[0.001749665,0.0001202417,0.0006834838,0.0002203243,0.0001910223,0.0004530378,0.0002080546,0.0008425668,0.0006384347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006663164,"about_ca_system_score_gemma":0.0006429747,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001100519,"about_ca_topic_score_gemma":0.002864007,"domain_scores_codex":[0.9996736,0.0001120902,0.00003012433,0.00005627653,0.00007404631,0.00005384436],"domain_scores_gemma":[0.9992919,0.0002133834,0.0002090922,0.00006346326,0.0001117411,0.0001103968],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1879899,0.002323117,0.1578101,0.0008035696,0.002499383,0.0002911905,0.0001498937,0.001309489,0.03340004,0.00078757,0.01115469,0.601481],"study_design_scores_gemma":[0.02218696,0.06257556,0.8252706,0.0003818964,0.006972414,0.001979235,0.0003685412,0.00742646,0.02246159,0.002027709,0.04823492,0.0001141861],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885308,0.004250411,0.0002353148,0.0010075,0.0001642962,0.00004784965,0.001266827,0.00005259784,0.004444371],"genre_scores_gemma":[0.9949226,0.001247812,0.0003792922,0.0004950244,0.0001358004,0.00003982076,0.001082862,0.00001834719,0.001678467],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003635712,"threshold_uncertainty_score":0.01216263,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01720813783629397,"score_gpt":0.4332956738272455,"score_spread":0.4160875359909516,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}